BLFS · As filed with the SEC
Biolife Solutions cash flow statement, by fiscal year
The statement as Biolife Solutions presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Net loss | (4,595) | (20,184) | (66,427) | (139,805) |
| Impairment of intangible assets | — | — | — | 110,364 |
| Impairment of intangible assets | 0 | 0 | 5,758 | — |
| Impairment of long-lived assets | 0 | 0 | 9,727 | — |
| Gain on settlement of Global Cooling escrow | — | — | (5,115) | — |
| Gain on settlement of Global Cooling escrow | 0 | 0 | — | — |
| Depreciation | 2,253 | 5,160 | 7,114 | 6,775 |
| Amortization of intangible assets | — | — | 5,181 | 9,697 |
| Amortization of intangible assets | 2,434 | 3,501 | — | — |
| Amortization of loan costs | 0 | 0 | 13 | 18 |
| Stock-based compensation | 22,993 | 30,923 | 31,670 | 25,334 |
| Non-cash lease expense | — | — | 404 | 3,486 |
| Non-cash lease expense | 1,875 | 424 | — | — |
| Deferred income tax expense (benefit) | 65 | (64) | (62) | (5,238) |
| Change in fair value of contingent consideration | 0 | 0 | (2,193) | (4,754) |
| Change in fair value of warrant liability | — | — | 0 | 0 |
| Change in fair value of investments | — | — | — | (697) |
| Change in fair value of equity investment and other | (983) | 4,074 | 0 | — |
| Accretion of investments | (736) | (474) | (1,262) | (447) |
| Gain on acquisition of Sexton Biotechnologies, Inc. | — | — | 0 | 0 |
| Stock issued for services | — | — | — | 0 |
| Loss on disposal of assets held for rent, net | 510 | 567 | 594 | 773 |
| Loss on disposal of property and equipment, net | 11 | 154 | 633 | 745 |
| Forgiveness of loans payable | — | — | 0 | 0 |
| IPR&D expense | 15,521 | — | — | — |
| Net gain on disposal of subsidiaries | (10,324) | (15,877) | — | — |
| Other | — | 0 | 0 | 166 |
| Change in operating assets and liabilities | ||||
| Accounts receivable, trade, net | 264 | (2,899) | 15,351 | (10,753) |
| Inventories | (1,268) | 781 | (8,552) | (6,559) |
| Prepaid expenses and other current assets | — | — | — | 26 |
| Prepaid expenses and other current assets | (3,039) | (2,407) | 137 | — |
| Accounts payable | (2,086) | 26 | (8,425) | 414 |
| Accrued expenses and other current liabilities | (1,144) | 6,485 | 2,002 | 1,787 |
| Sales taxes payable | (1,905) | (973) | 1,311 | 1,526 |
| Warranty liability | — | — | (454) | (1,086) |
| Warranty liability | 5 | (528) | — | — |
| Other | 264 | (258) | 97 | (260) |
| Net cash provided by (used in) operating activities | 20,115 | 8,431 | (12,498) | (8,488) |
| Cash flows from investing activities | ||||
| Cash acquired in acquisition of Global Cooling, Inc. and Sexton Biotechnologies, Inc. | — | — | 0 | 0 |
| IVexSol Preferred Stock Investment | — | — | — | 0 |
| PanTHERA Cryosolutions Investment | — | — | — | 0 |
| Purchases of property and equipment | (9,478) | (3,227) | (6,381) | (10,385) |
| Deposits on property and equipment | — | — | — | 0 |
| Purchases of assets held for rent | (886) | (2,068) | (4,856) | (3,536) |
| Deposits on assets held for rent | — | — | — | 0 |
| Proceeds from sale of marketable securities | — | — | — | 420 |
| Maturities of marketable securities | — | — | — | 8,500 |
| Proceeds from sale of equipment | — | — | 0 | 0 |
| Proceeds from sale of available-for-sale securities | 6,829 | 3,518 | 3,469 | — |
| Maturities of available-for-sale securities | 34,764 | 18,400 | 52,700 | — |
| Investment in available-for-sale securities | (114,063) | (18,415) | (27,095) | (53,116) |
| Purchases of intangible assets | 0 | (300) | — | — |
| Investment in IPR&D | (10,221) | — | — | — |
| Investment in convertible promissory note | (2,000) | — | — | — |
| Proceeds from sale of divested entities | 23,516 | 73,431 | — | — |
| Payments on divestiture of Global Cooling | 0 | (13,039) | — | — |
| Net cash (used in) provided by investing activities | (71,539) | 58,300 | 17,837 | (58,117) |
| Cash flows from financing activities | ||||
| Paycheck Protection Program CARES Act | — | — | — | 0 |
| Equipment Loans | — | — | — | 0 |
| Paycheck Protection Program CARES Act | — | — | — | 0 |
| Equipment Loans | — | — | — | (498) |
| Proceeds from term loan | — | — | — | 20,000 |
| Payments on term loan | — | — | — | (1,666) |
| Payments of contingent consideration | — | — | — | 0 |
| Proceeds from term loan | — | 0 | 0 | — |
| Payments on term loan | (10,000) | (5,000) | (300) | — |
| Payments on equipment loans | 0 | (1,608) | (198) | — |
| Financed Insurance Premium | — | — | — | (1,375) |
| Proceeds from equipment loans | — | — | 0 | — |
| Issuance of common stock | 0 | 0 | 10,244 | — |
| Common Stock, 2020 | — | — | — | 0 |
| Fees paid related to issuance of common stock | — | 0 | 0 | (131) |
| Proceeds from line of credit | — | — | 0 | 0 |
| Payments on line of credit | — | — | 0 | 0 |
| Proceeds from exercise of common stock options | 18 | 202 | 507 | 323 |
| Proceeds from exercise of warrants | — | — | — | 0 |
| Proceeds from financed insurance premium | 0 | 2,094 | 2,639 | — |
| Payments on financed insurance premium | (975) | (2,397) | (2,365) | — |
| Other | 33 | (74) | 64 | (337) |
| Net cash (used in) provided by financing activities | (10,924) | (6,783) | 10,591 | 16,316 |
| Net (decrease) increase in cash and cash equivalents | (62,348) | 59,948 | 15,930 | (50,289) |
| Cash and cash equivalents – beginning of period | 95,386 | 35,438 | 19,473 | 69,870 |
| Effects of currency translation on cash and cash equivalents | 0 | 0 | 35 | (108) |
| Cash and cash equivalents – end of period | 33,038 | 95,386 | 35,438 | 19,473 |
| Non-cash investing and financing activities | ||||
| Cashless exercise of warrants reclassified from warrant liability to common stock | — | — | 0 | 0 |
| Global Cooling, Inc. and Sexton Biotechnologies | — | — | 0 | 0 |
| SciSafe | — | — | 2,263 | 817 |
| Equipment acquired under operating leases | — | — | — | 243 |
| Equipment acquired under finance leases | — | — | — | 0 |
| Assets acquired under operating leases | 0 | 5,833 | 880 | — |
| Assets acquired under finance leases | 0 | 0 | 1,682 | — |
| Purchase of property and equipment not yet paid | 0 | 107 | 359 | 478 |
| Unrealized loss (gain) on available-for-sale securities | 108 | (18) | (56) | 50 |
| Unrealized gain on currency translation | — | 0 | (12) | 0 |
| Stock issued as bonus consideration | — | — | — | 0 |
| Unrealized gain on currency translation | 0 | — | — | — |
| Non-cash acquisition of PanTHERA | 5,300 | — | — | — |
| Cashless issuance of SciSafe earnout shares | 0 | 0 | — | — |
| Returned shares from settlement of Global Cooling escrow | 0 | 0 | (5,115) | — |
| Cash interest paid | 762 | 1,608 | 1,927 | 586 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.